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Alteration of metabolite profiling by cold
atmospheric plasma treatment in human
myeloma cells
Dehui Xu1*†, Yujing Xu1, Ning Ning2, Qingjie Cui2, Zhijie Liu1, Xiaohua Wang1, Dingxin Liu1, Hailan Chen3
and Michael G. Kong1,3,4*†

Abstract
Background: Despite new progress of chemotherapy in multiple myeloma (MM) clinical treatment, MM is still a
refractory disease and new technology is needed to improve the outcomes and prolong the survival. Cold atmospheric plasma is a rapidly developed technology in recent years, which has been widely applied in biomedicine.
Although plasma could efficiently inactivate various tumor cells, the effects of plasma on tumor cell metabolism have
not been studied yet.
Methods: In this study, we investigated the metabolite profiling of He plasma treatment on myeloma tumor cells
by gas-chromatography time-of-flight (GC-TOF) mass-spectrometry. Meanwhile, by bioinformatic analysis such as
GO and KEGG analysis we try to figure out the metabolism pathway that was significantly affected by gas plasma
treatment.
Results: By GC-TOF mass-spectrometry, 573 signals were detected and evaluated using PCA and OPLS-DA. By KEGG
analysis we listed all the differential metabolites and further classified into different metabolic pathways. The results
showed that beta-alanine metabolism pathway was the most significant change after He gas plasma treatment in
myeloma cells. Besides, propanoate metabolism and linoleic acid metabolism should also be concerned during gas
plasma treatment of cancer cells.
Conclusions: Cold atmospheric plasma treatment could significantly alter the metabolite profiling of myeloma
tumor cells, among which, the beta-alanine metabolism pathway is the most susceptible to He gas plasma treatment.
Keywords: Cold atmospheric plasma, Multiple myeloma, Metabolite profiling, Mass spectrometry, KEGG analysis,
Beta-Alanine metabolism
Background
Multiple myeloma (MM) is a malignant tumor caused
by abnormal proliferation of monoclonal plasma cells,
accounting for 1% of all tumors and 13% of hematological
malignancies [1, 2]. After the initial onset of remission,
relapse will occur and only 25% of patients have a survival of more than 5 years after receiving chemotherapy
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[3]. It is characterized by an increase in abnormal plasma
cells that produce monoclonal immunoglobulin and
malignant proliferation in the bone marrow, causing fractures and bone marrow failure [4, 5]. The current clinical
treatment of MM includes radiation therapy, bone marrow transplantation and chemotherapeutics treatment
[6, 7]. Radiation therapy, however, will inevitably damage
human normal cells while killing cancer cells. Bone marrow transplantation may result in postoperative autologous rejection. Chemotherapeutics may have serious
side effects and usually lead to drug resistance. Therefore, MM is a refractory disease and new technology and
treatment tools need to be developed for MM therapy.
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Cold atmospheric plasma (CAP) is a new technology rapidly developed in recent years. It is produced
under atmospheric pressure with low gas temperature
and high activity of reactive species, which has aroused
widespread concern especially in biomedical application, such as disinfection of bacteria, application in dermatology and dentistry, cell transfection, wound healing
and cancer treatment [8–17]. It is widely reported that
plasma could efficiently inactive tumor cells in various
types of cancer, including lung cancer, leukemia, intestinal cancer, melanoma, cervical cancer, glioma, multiple
myeloma, pancreatic cancer et al. [18–28]. The induction of apoptosis in cancer cells has been widely reported,
and the mechanism of plasma-induced apoptosis is being
increasingly understood. However, the effects of plasma
on tumor cell metabolism have not been reported yet.
Cell metabolism is a general term for a series of ordered
chemical reactions that take place in the cells to survive.
These reaction processes allow cells to grow and reproduce, maintain their functions and respond to the external environment, including the metabolism of matter and
energy. Tumor cells provide a source of their aberrant
proliferation through a systematic reprogramming of cellular metabolism [29, 30]. These changes in metabolism
involve the production of energy required for cell division, the regulation of intracellular redox status, and the
breakdown and synthesis of nutrients after ingestion,
thereby altering the flux of metabolites inside and outside
cells and redistributing them to the corresponding metabolic pathways, to meet the needs of maintaining the
malignant transformation phenotype of cells [31]. Therefore, understanding the effects of gas plasma on tumor
cell metabolism is of great significance. In this study,
we explored the influence of gas plasma on tumor cell
metabolism profiling for the first time. By metabonomics,
we found that the metabolism of myeloma tumor cells
was greatly changed after He plasma treatment. Notably,
beta-alanine metabolism pathway was found to be the
major target that was affected by gas plasma treatment,
indicating that beta-alanine might play an important role
in the interaction of gas plasma with tumor cells.

Methods
Gas plasma generation

In this study, we used a plasma jet which was described in
our previous research to generate the cold atmospheric
plasma. Characters of the plasma generation and electronic parameters were illustrated in our previous works
[17, 28, 32]. The He plasma was generated at 10 kHz/8 kV
with a He gas flow of 2 SLM.
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Cell culture condition

The LP-1 multiple myeloma cell line was used in this
study. LP-1 cells were grown in Roswell Park Memorial Institute (RPMI) 1640 medium supplemented with
10% fetal calf serum, 100 U/mL penicillin, and 50 µg/mL
streptomycin (Gibco-Invitrogen, Carlsbad, CA, 15140122). The cells were cultured at 37 °C in an incubator
(Thermo Scientific, Waltham, MA, USA) containing 5%
CO2. The medium was refreshed 24 h before performing
experiments.
Cell viability was measured by A Cell-Titer-Glo® luminescent cell viability assay kit (Promega, Madison, WI,
USA) which based on the production of ATP in viable
cells. 100 μL of samples and 100 μL of Cell-Titer-Glo®
reagent were added to the opaque-walled plate and was
incubated at room temperature for 10 min. The luminescence was detected by a microplate reader (Thermo
Scientific Varioskan Flash, Waltham, MA, USA) with the
protocol of “luminometric” measurement.
Cell viability assessment

Solvents and reagents

We bought L-2-chlorophenylalanine from Hengbai Biotechnology Co Ltd (Shanghai, China), while Methoxy
amination hydrochloride (chromatographic grade), pyridine and chloroform (HPLC grade) were from Admas
(Shanghai, China). Moreover, BSTFA (including 1%
TMCS, v/v) was purchased from REGIS Technologies
Inc (Morton Grove, IL, USA) and methyl alcohol (HPLC
grade) was purchased from ANPEL Laboratory Technologies Inc (Shanghai, China). Saturated fatty acid methyl
fat (C8, C9, C10, C12, C14, C16, C18, C20, C22, C24)
was bought from Dr. Ehrenstorfer (Augsburg, Germany).
Deionized water was used throughout this experiment
(Thermo; Waltham, MA, USA).
Sample collection

3 × 105 cells/well in 300 μL of medium were seeded in
24-well plate, then the wells which treated with 40 s of He
plasma were considered as plasma treatment group and
the remains were control group, and each group had 5
duplicates/samples. After 24 h incubation, cells were collected and counted to ensure the cell number was about
1 × 107 cells/sample. Cells were harvested by centrifugation at 4 °C for 5 min with the speed of 1200 rpm and
washed with PBS three times at 4 °C for 3 min with the
speed of 900 rpm. Then the cell pellet in EP tube was rapidly put in liquid nitrogen for 5 min and stored in − 80 °C
refrigerator until analysis.

Xu et al. Cancer Cell Int (2018) 18:42

Sample preparation

Before metabolite analysis, sample was mixed with
0.6 mL of extraction liquid (Vmethanol:VChlorofrom = 3:1)
in 2 mL EP tube and 10 μL of L-2-chlorophenylalanine
(1 mg/mL stock in d
 H2O) which was regarded as internal standard. After 30 s of vortex mixing, steel balls were
added and grinded for 4 min at 45 Hz followed by treating with ultrasound for 5 min in ice water, then repeating
this step for 3 times. The supernatant (0.5 mL) was transferred into a fresh 2 mL GC/MS glass vial after centrifuging for 15 min at 13,000 rpm, 4 °C. Next, the extracted
metabolites were dried in a vacuum concentrator without
heating and 30 μL of methoxy amination hydrochloride
was added. After incubating in oven at 80 °C for 30 min,
40 μL of the BSTFA regent (1% TMCS, v/v) was mixed
well with the sample aliquots and cultured for 1.5 h for
70 °C to obtain the derived metabolites for GC–MS
analysis.
GC‑TOFMS analysis

GC-TOFMS analysis was performed using an Agilent 7890 gas chromatograph system coupled with a
Pegasus HT time-of-flight mass spectrometer. The system utilized a DB-5MS capillary column coated with
5% diphenyl cross-linked with 95% dimethylpolysiloxane (30 m × 250 μm inner diameter, 0.25 μm film thickness; J&W Scientific, Folsom, CA, USA). A 1 μL aliquot
of the analyte was injected in splitless mode. Helium
was used as the carrier gas, the front inlet purge flow
was 3 mL min−1, and the gas flow rate through the column was 1 mL min−1. The initial temperature was kept
at 80 °C for 1 min, then raised to 290 °C at a rate of
10 °C min−1, then kept for 12 min at 290 °C. The injection, transfer line, and ion source temperatures were 280,
295, and 220 °C, respectively. The energy was − 70 eV in
electron impact mode. The mass spectrometry data were
acquired in full-scan mode with the m/z range of 50–600
at a rate of 12.02 spectra per second after a solvent delay
of 8.45 min.

Results
Metabolic profiling of gas plasma‑treated cells samples
by GC‑TOF

We investigated a total of 12 samples. Six were LP-1 cells
with gas flow as control group, another six samples were
LP-1 cells treated with He plasma for 1 min. With gas
chromatography-time of flight mass spectrometry (GCTOF), around 573 signals were detected per sample using
mass spectral deconvolution software for peak detection.
However, some of these signals were not consistently
found in other samples or were of too low abundance or
too poor spectral quality to be unambiguously assigned
to unique metabolites. We have normalized with internal
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standard (IS) and finally 561 valid peaks were remained
for further analysis. Details of these 561 peaks were listed
in Additional file 1: Table S1. Figure 1 shows the overall
representative GC-TOF chromatograms of control group
and plasma treatment group.
Unsupervised evaluation of metabolite signatures using
PCA and OPLS‑DA

After obtaining the raw data, we carry out a series of
multivariate variable pattern recognition analysis, which
is the principal component analysis (PCA). Using the
SIMCA software (V14.1, MKS Data Analytics Solutions,
Umea, Sweden), the data is logarithmic (LOG) formatted (CTR) formatted and then automatically modeled
[6]. The parameters of the PCA model are shown in the
statistical model parameter Table 1. Since the two groups
of samples are not very significant, the sample is basically
in the 95% confidence interval (Hotelling’s T-squared
ellipse), this data need to be further analyzed.
Therefore, we use the orthogonal least squares—discriminant analysis (orthogonal projection to latent
structures-discriminant analysis, OPLS-DA) statistical methods to further analyze the results. Through the
OPLS-DA analysis, we can filter out the orthogonal variables that are not related to the categorical variables in
the metabolites, and analyze the differences between the
non-orthogonal and orthogonal variables to obtain the
more reliable metabolites. LOGG software was added to
the data using SIMCA software (V14.1, MKS Data Analytics Solutions, Umea, Sweden). First, the first principal
component was analyzed by OPLS-DA model. The quality of the model was verified by sevenfold cross validation (model-to-class variability Y) and Q2 (predictability
of the model) to determine the validity of the model by
cross validation. Finally, Permutation test), randomly different times to change the order of the variable Y order
to get a different random Q2 value, the model validity for
further testing. For more information on the OPLS-DA
model, refer to the statistical model parameter Table 2.
As shown in Fig. 2a, the abscissa t [1] P represents the
predicted principal component score of the first principal component, and the ordinate t [1] O represents the
orthogonal principal component score, and the scatter
shape and color represent different experimental groups.
It shows that the two groups of samples are more significant, the sample is basically in the 95% confidence interval (Hotelling’s T-squared ellipse). The permutation test
establishes the corresponding OPLS-DA model to obtain
the random model R2 and Q2 values by randomly changing the permutation order of the categorical variable Y,
the number of times (n = 200), the avoidance of the overfitting of the test model and the evaluation of the model
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Fig. 1 Representative GC-TOF chromatograms of control group and plasma treatment group by mass spectra
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Table 1 Statistical model parameters table of PCA model
Model

Type

A

N

R2X (cum)

Model 1

PCA

3

12

0.569

Significance has an important role. Figure 2b shows the
replacement test for the OPLS-DA model.
Identification of differential metabolites by supervised
analysis

We used the generally recognized standard by academia,
that is P value of student’s t test is less than 0.05, and
the variable importance in the projection (VIP) of the
first principal component of OPLS-DA model is greater
than 1, to determine the differential metabolites between
control and plasma treatment group. Additional file 1:
Table S1 lists all the differences in metabolite screening,
and was further illustrated in the form of volcano plot
(Fig. 3). As shown in the final screening result, the significant uptake of the metabolites was displayed in red,
while the significant down-regulation of the metabolites
was shown in blue.
KEGG analysis of differential metabolites

The complex metabolic responses and their regulation
in organisms are not carried out separately, and often
complex pathways and networks are formed by different
genes and proteins. Their interaction and mutual regulation eventually lead to systemic changes in the metabolic
group. The analysis of these metabolic and regulatory
pathways can provide a more comprehensive and systematic understanding of the biological processes such as
changes in the biological processes, the pathogenesis of
the disease or the mechanism of the drug.
The kyoto encyclopedia of genes and genomes (KEGG)
pathway database (http://www.kegg.jp/kegg/pathway.
html) is based on the functional information of genes and
genomes, and the metabolic response is clues, the possible metabolic pathways and the corresponding regulatory
proteins, in a graphical way to show the cell physiological
and biochemical processes. First, we mapped all the 561
metabolites to the Homo sapiens in the KEGG PATHWAY database. The mapping results are shown in Additional file 1.
Based on the mapping results, we sort out all the pathways for the differential metabolite mapping, as shown
in Additional file 2. After that, we labeled the differential

metabolites on the KEGG pathway. As shown in Fig. 4,
red represented up-regulation while bright blue represented down-regulation. And the black indicated that
metabolites were detected but not significantly different.
Metabolic pathway analysis of differential metabolites

KEGG analysis only found all the pathways that was relevant to these differential metabolites, to further analyze the most relevant pathways associated with these
metabolite differences, a comprehensive analysis of the
pathways of differential metabolites (including enrichment analysis and topological analysis) was carried out.
We mapped these differential metabolites to the metabolites database such as KEGG, PubChem et al. and the
metabolite mapping table was shown in Additional file 3.
After obtaining the matching information of the different metabolites, we searched and analyzed the metabolic
pathways in Homo sapiens database. An example of a
metabolic pathway analysis table is given in Additional
file 4. The results of the metabolic pathway analysis were
presented as a bubble chart (Fig. 5). Each bubble in the
bubble diagram represents a metabolic pathway. The
abscissa and bubble size of the bubble indicate the size of
the influence factor in the topology analysis. The larger
the size is, the greater the influence factor is. The vertical
and bubble color of the bubble indicate the enrichment
analysis P value (negative natural logarithm, that is-ln P
value), the deeper the color P value is smaller, the more
significant degree of enrichment. From this chart we
could clear figure out that beta-alanine metabolism pathway was the most significant changes after He gas plasma
treatment in LP-1 cells. Besides, propanoate metabolism
and linoleic acid metabolism should also be concerned
during gas plasma treatment of cancer cells.
Hierarchical clustering analysis of differential metabolites

The differential metabolites obtained by the above analysis are often biologically consistent and functional similarity/complementarity, or positive regulation/negative
regulation by the same metabolic pathway, which will
present similar or opposite expression characteristics
between different experimental groups. The hierarchical
clustering analysis of these characteristics will clear classify the metabolites with the same and different characteristics between the experimental groups.
We calculated the Euclidean distance matrix from
the plasma treatment group to quantify the differential metabolites of the control group. The results were

Table 2 Statistical model parameters table of OPLS-DA model
Model

Type

A

N

R2X (cum)

R2Y (cum)

Q2 (cum)

Model 2

OPLS-DA

1+1+0

12

0.486

0.985

0.81

Xu et al. Cancer Cell Int (2018) 18:42
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Fig. 2 The score scatter plot of (a) OPLS-DA model and permutation test of (b) OPLS-DA model

visualized in a heatmap that was combined with hierarchical clustering of samples and metabolites (Fig. 6). The
color patches at different positions represent the relative

expression levels of the corresponding metabolites. It can
be seen that there are obvious differences in metabolic
grouping patterns after He plasma treatment.

Xu et al. Cancer Cell Int (2018) 18:42
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− log10 P −value
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not significant
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Fig. 3 Volcano plot for differential metabolites between control and plasma treatment group

Fig. 4 Metabolic pathways with red/blue dots representing the differentially expressed compounds
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beta−Alanine metabolism

9

− ln P −value

− ln P −value

Propanoate metabolism

2.5 5.0 7.5 10.0

6

Impact
0
Arginine and proline metabolism

0.656

Pentose and glucuronate interconversions
Sphingolipid metabolism

3

Alanine, aspartate and glutamate metabolism
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Pantothenate and CoA biosynthesis
Galactose metabolism

Linoleic acid metabolism

Arachidonic acid metabolism

0
0.0

0.2

Impact

0.4

0.6

Fig. 5 Bubble chart of the metabolic pathway analysis

Discussion
Energy and material metabolism is the basic guarantee for
cell survival. Adenosine triphosphate (ATP) is a currency
in the cell that is used to store and deliver energy. In normal tissues, 90% of the ATP comes from oxidative phosphorylation, whereas only 10% comes from glycolysis [33].
In aerobic conditions, glycolysis is inhibited, known as the
Pasteur effect. However, Warburg found that tumor cells
are still prevalent with high rates of glucose uptake even
under oxygenated conditions. The increased glycolytic
metabolism and increased metabolites of lactate, which
are ubiquitous in various tumor cells, called as the Warburg effect [34, 35]. Although the efficiency of glycolysis is
low, tumor cells can benefit from glycolysis: Firstly, Due to
the rapid growth of tumor cells, there is a great demand for
energy and more glycolytic production of ATP is required.
Secondary, glycolysis intermediates such as 6-phosphate
glucose, pyruvate can synthesize fatty acids, nucleic acids
which are important for cell metabolism and biosynthesis.
Therefore, the energy and material metabolism of tumor

cells and normal cells are quite different. Atmospheric
cold plasma, as a newly developed technology, can selectively induce tumor cell death. In addition, some related
apoptosis pathway factors were reported although more
mechanism need to be investigated. In our study, instead
of study on the single apoptotic protein, we investigated
the whole metabolism profiling to understand the effect
of plasma on the metabolism of tumor cells. Because
the metabolomic data typically contains a large number
of variables that are interrelated, multivariate statistical
methods such as PCA and OPLS-DA were used in this
study [36]. We demonstrated the large scale metabolic
profiling using GC-TOF mass spectrometry and found
numerous significant differences between the gas control group and the plasma treatment group in myeloma
tumor cells. By KEGG analysis of the metabolic pathways
we found that beta-alanine metabolism pathway was the
most significant changes after He gas plasma treatment
in myeloma LP-1 cells. Alanine, beta-alanine and sarcosine share the same chemical formula C
 3H7NO2, but are

Xu et al. Cancer Cell Int (2018) 18:42

Page 9 of 11

5−Methoxytryptamine 2
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Fig. 6 Heatmap of hierarchical clustering analysis for plasma treatment and control group

structurally different. By GC–TOFMS analysis, beta-alanine is easy to separate from alanine and sarcosine duo
to its distinct mass spectrum [37]. Beta-alanine is a direct
precursor of pantothenic acid (PA) which is needed for
the synthesis of coenzyme A (CoA). In the tricarboxylic
acid (TCA) cycle, CoA is important for pyruvate to enter
as acetyl-CoA, and for α-ketoglutarate to be transformed
to succinyl-CoA [38]. In addition, CoA is involved in the
biosynthesis of many important compounds such as fatty
acids, cholesterol, and acetylcholine [39]. Therefore, by He
plasma treatment, beta-alanine metabolism in myeloma
tumor cells was suppressed, which disturbing the energy
and material metabolism of the tumor cells and results in
tumor cells death. Our data illustrated some details about
the dysregulation of metabolism profiling by gas plasma
for the first time. Although more researches need to be
done to further analyze the mechanism under molecular
microstructure, this study gives a general direction for
further study. Meanwhile, more tumor cell lines and the
treatment by different types of gas plasma devices will be
done for metabolite profiling analysis, to further illustrate

the biological effects in various tumor cells by different
reactive species in gas plasma.

Conclusions
In conclusion, we demonstrated the effects of gas plasma
on tumor cell metabolism by GC-TOF mass-spectrometry for the first time. By bioinformatics analysis we
showed that plasma treatment could significantly alter
the metabolite profiling of tumor cells. In addition, betaalanine metabolism pathway was the most susceptible to
plasma treatment, which might be instructive to further
detail the mechanism of biological effects induced by
plasma treatment in tumor cells.
Additional files
Additional file 1: Table S1. KEGG metabolite mapping.
Additional file 2: Table S2. KEGG pathway.
Additional file 3: Table S3. Pathway metabolite mapping.
Additional file 4: Table S4. Pathway analysis.
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